Telix Pharmaceuticals said its prostate-specific membrane antigen PET radiopharmaceutical Illuccix is now available to order from 117 pharmacies in the Telix network.
Clinicians in Indiana, New York City, and the state of Washington are among the first to administer Illuccix, demonstrating coast-to-coast availability of the new radiotracer for prostate cancer, the company said. The Telix network covers about 85% of PET imaging sites across the U.S., with more sites to be added over the coming months, Telix added.
Illuccix was cleared by the U.S. Food and Drug Administration in December 2021. It is a kit for preparing gallium-68 gozetotide (Ga-68 PSMA-11) injections for PET imaging in men with suspected prostate cancer metastasis who are candidates for initial definitive therapy or whose cancer may have recurred based on elevated serum prostate-specific antigen (PSA) levels.
